DNA Vaccine for Prostate Cancer
Author Information
Author(s): Pavlenko M, Roos A-K, Lundqvist A, Palmborg A, Miller A M, Ozenci V, Bergman B, Egevad L, Hellström M, Kiessling R, Masucci G, Wersäll P, Nilsson S, Pisa P
Primary Institution: Karolinska Institute
Hypothesis
Can a DNA vaccine encoding prostate-specific antigen induce an immune response in patients with hormone-refractory prostate cancer?
Conclusion
The DNA vaccine was found to be safe and could induce a PSA-specific immune response in some patients.
Supporting Evidence
- The vaccine was produced under Good Manufacturing Practice conditions.
- No dose-limiting toxicity occurred at any dose level tested.
- Two patients who developed a cellular immune response exhibited disease stabilization.
Takeaway
This study tested a new vaccine to help the body fight prostate cancer, and it showed that the vaccine is safe and can help the body recognize the cancer better.
Methodology
Nine patients received a DNA vaccine at three different dose levels, along with cytokine adjuvants, and were monitored for immune responses and side effects.
Potential Biases
The study design did not allow for assessment of the effects of adjuvants or optimal vaccine dose.
Limitations
The study had a small sample size and was not designed to assess maximum tolerated dose.
Participant Demographics
Patients were diagnosed with advanced hormone-refractory prostate cancer, with varying ages and disease characteristics.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website